Education
About Us
Working with TipRanks
Follow Us
Bausch + Lomb Corporation (BLCO)
:BLCO
BLCO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.45 - $21.69
Previous CloseN/A
Volume107.99K
Average Volume (3M)514.99K
Market Cap
$5.31B
Enterprise Value$9.36B
Total Cash (Recent Filing)$272.00M
Total Debt (Recent Filing)$4.96B
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Oct 29, 2025EPS Estimate
0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding353,865,780
10 Day Avg. Volume510,251
30 Day Avg. Volume514,990
Financial Highlights & Ratios
PEG Ratio-0.93
Price to Book (P/B)0.98
Price to Sales (P/S)1.33
P/FCF Ratio-107.69
Enterprise Value/Market Cap1.76
Enterprise Value/Revenue1.91
Enterprise Value/Gross Profit3.21
Enterprise Value/Ebitda26.66
Forecast
1Y Price Target
$14.50Price Target Upside-3.40% Downside
Rating ConsensusHold
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Financial GuidanceBLCO raised its FY25 revenue and EBITDA guidance, indicating optimism in overcoming challenges like the enVista recall and tariff headwinds.
Product GrowthMiebo sales were a key growth driver, contributing significantly to overall BLCO growth with strong optimism for continued growth.
Bears Say
Investor SentimentInvestor interest will be limited until there is more visibility on the separation from Bausch Health.
Market CompetitionMiebo and Xiidra together saw a slight decline in their dry eye new prescription share in May, which could indicate increasing competition in the market.
Bausch + Lomb Corporation News
BLCO FAQ
What was Bausch + Lomb Corporation’s price range in the past 12 months?
Bausch + Lomb Corporation lowest stock price was $10.45 and its highest was $21.69 in the past 12 months.
What is Bausch + Lomb Corporation’s market cap?
Bausch + Lomb Corporation’s market cap is $5.31B.
When is Bausch + Lomb Corporation’s upcoming earnings report date?
Bausch + Lomb Corporation’s upcoming earnings report date is Oct 29, 2025 which is in 32 days.
How were Bausch + Lomb Corporation’s earnings last quarter?
Bausch + Lomb Corporation released its earnings results on Jul 30, 2025. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.062 by $0.008.
Is Bausch + Lomb Corporation overvalued?
According to Wall Street analysts Bausch + Lomb Corporation’s price is currently Overvalued.
Does Bausch + Lomb Corporation pay dividends?
Bausch + Lomb Corporation does not currently pay dividends.
What is Bausch + Lomb Corporation’s EPS estimate?
Bausch + Lomb Corporation’s EPS estimate is 0.16.
How many shares outstanding does Bausch + Lomb Corporation have?
Bausch + Lomb Corporation has 353,865,780 shares outstanding.
What happened to Bausch + Lomb Corporation’s price movement after its last earnings report?
Bausch + Lomb Corporation reported an EPS of $0.07 in its last earnings report, beating expectations of $0.062. Following the earnings report the stock price went down -6.416%.
Which hedge fund is a major shareholder of Bausch + Lomb Corporation?
Currently, no hedge funds are holding shares in BLCO
Bausch + Lomb Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$14.50 (-3.40% Downside)
$14.50 (-3.40% Downside)
Blogger Sentiment
Bullish
BLCO Sentiment 70%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 569.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.44%
12-Months-Change
Fundamentals
Return on Equity
-4.22%
Trailing 12-Months
Asset Growth
4.39%
Trailing 12-Months
Company Description
Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
BLCO Company Deck
BLCO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with notable achievements in contact lens growth, dry eye treatments, and increased revenue guidance, but also faced challenges from the enVista recall and U.S. Generics decline. The sentiment is neutral as highlights and lowlights are balanced.View all BLCO earnings summariesBLCO Stock 12 Month Forecast
Average Price Target
$14.50
▼(-3.40% Downside)
Technical Analysis
Ownership Overview
0.60% Insiders
0.53% Mutual Funds
6.67% Other Institutional Investors
91.98% Public Companies and
Individual Investors